Pyruvate kinase activators for use in treating blood disorders

A compound represented by the following structural formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is hydrogen, an optionally substituted alkyl, an optionally substituted haloalkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, —ORo1, —C(═O)Rc1, or a nitrogen protecting group;
• wherein:
• Ro1 is hydrogen, optionally substituted alkyl, or an oxygen protecting group;
• Rc1 is optionally substituted alkyl or —N(Rcn)2, wherein each instance of Rcn is independently hydrogen, —C1-6 alkyl, or a nitrogen protecting group;
• R2 and Q are each independently an optionally substituted 5- or 6-membered monocyclic heteroaryl;
• Ra and Rb are each independently hydrogen, a halogen, —CN, —NO2,—N3, an optionally substituted alkyl, —ORo3, —N(Rn1)2, —C(═O)N(Rn1)2, or —C(═O)Rc2;
• or alternatively Ra and Rb can be taken together with the carbon atom to which they are attached to form an optionally substituted cycloalkyl or an optionally substituted heterocyclyl;
• wherein:
• each instance of Rn1 is independently hydrogen, an optionally substituted —C1-C6 alkyl, or a nitrogen protecting group;
• Ro3 is hydrogen, an optionally substituted —C1-C6 alkyl, or an oxygen protecting group;
• and
• Rc2 is an optionally substituted —C1-C6 alkyl;
• and
• Rj and Rk are each independently hydrogen, a halogen, —CN, —ORo7, —N(Rn5)2, —N(Rn5)C(═O)Rc5, —C(═O)N(Rn5)2, —C(═O)Rc5, —C(═O)ORo7, —SRjs, —S(═O)2Rjs, —S(═O)Rjs, or an optionally substituted —C1-C6 alkyl;
• or alternatively Rj and Rk can be taken together with the carbon atom to which they are attached to form C═O, an optionally substituted C1-C6 monocyclic cycloalkyl ring, or an optionally substituted C3-C6 monocyclic heterocyclyl ring;
• wherein:
• each instance of Rn5 is independently hydrogen, an optionally substituted —C1-C6 alkyl, —ORo8, or a nitrogen protecting group, wherein Ro8 is hydrogen, an optionally substituted —C1-C6 alkyl, or an oxygen protecting group;
• each instance of Ro7 is independently hydrogen, an optionally substituted —C1-C6 alkyl, or an oxygen protecting group;
• each instance of Rc5 is independently an optionally substituted —C1-C6 alkyl;
• and
• each instance of Rjs is independently an optionally substituted —C1-C6 alkyl, an optionally substituted C6-12 aryl, an optionally substituted heteroaryl, or a sulfur protecting group.